Background {#Sec1}
==========

Ovarian cancer (OC) is a highly lethal gynecological cancer. Approximately 23% of gynecological cancers are ovarian in origin, but 47% of all deaths from cancer of the female genital tract occur in women with cancer of this organ. Malignant tumors of the ovaries occur at all ages with variation in histological sub-type by age \[[@CR1], [@CR2]\]. Established risk factors for epithelial ovarian tumors include reproductive risk factors and inherited pathological mutations in the BRCA1 and BRCA2 genes \[[@CR3], [@CR4]\]. Initially, OC lacks clear symptoms, which prevents early diagnosis and treatment. Many potential biomarkers have been identified or used in recent years in the diagnostics of ovarian cancer patients \[[@CR5], [@CR6]\]. At present, CA 125 (carbohydrate antigen 125) \[[@CR7]\] is the best-known ovarian cancer biomarker, although novel biomarkers such as HE4 (human epididymis protein 4), applicable to the diagnosis of this malignancy, have been researched recently \[[@CR7], [@CR8]\]. This glycoprotein belongs to a family of protease inhibitors and it is presumed to function as a is trypsin inhibitor. It is expressed in normal glandular epithelium of the reproductive tract, respiratory epithelium and distal renal tubules \[[@CR9], [@CR10]\]. In benign conditions, the highest HE4 concentrations have been observed in both women and men with renal failure. HE4 has been shown to be overexpressed in 93% of serous, 100% of endometrioid, and 50% of clear cell ovarian carcinomas. Similarly to other tumor markers, it is neither a strictly organ-specific nor a tumor-specific factor. Significant HE4 gene expression and strong immunoreactivity has been found in some lung, endometrial, renal, thyroid and breast carcinomas \[[@CR9], [@CR11]\]. When comparing the two aforementioned biomarkers it is believed that levels of HE4 are less frequently elevated in benign gynecological conditions than those of CA125 \[[@CR12]\].

Different types of proteins, other than the commonly accepted and used tumor markers - such as cytokines (M-CSF, VEGF) \[[@CR13], [@CR14]\] and metalloproteinases are currently being investigated \[[@CR15], [@CR16]\]. Metalloproteinases have the ability to degrade extracellular matrix proteins, thereby facilitating tumor invasiveness, which also occurs through their interaction with growth factors, cytokines and proteases \[[@CR17]\]. The tissue inhibitors of metalloproteinases (TIMPs: TIMP-1 and -2) regulate MMPs' activation by binding as a complex \[[@CR18]\]. MMP-7 (matrilysin) is the smallest proteinase from the entire metalloproteinases family with broad proteolytic activity against proteoglycans, elastin, laminin, collagens \[[@CR19]\]. Overexpression and increased serum levels of this metalloproteinase have been confirmed in prostate, lung, renal, colorectal or breast malignancies \[[@CR20]--[@CR24]\]. Some clinical studies have also revealed significantly elevated TIMP-1 levels in the plasma of patients with colorectal, prostate and pancreatic cancers, which was associated with worse clinical outcomes \[[@CR25]--[@CR27]\].

The aim of this study was to determine plasma levels of metalloproteinase 7 and its tissue inhibitor 1 in comparison to HE4 and CA125 plasma levels in epithelial ovarian cancer patients and in relation to the control groups: patients with benign ovarian tumors and healthy subjects. The diagnostic criteria (sensitivity, specificity, predictive values of positive and negative test results) and the receiver-operating characteristic curve (ROC) for parameters investigated alone and in combinations were defined. Furthermore, correlations between the biomarkers tested were established.

These data may be used in the evaluation of the usefulness of MMP-7 and TIMP-1 in diagnosing ovarian cancer and in discriminating it from benign ovarian tumors.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

Table [1](#Tab1){ref-type="table"} shows the tested groups. The study included 100 epithelial ovarian cancer patients (EOC) (sub-types *serous* and *endometrioid*) diagnosed by the Gynecology Group. Clinical stages and histological classification based on the criteria of the International Federation of Gynecology and Obstetrics (FIGO) and the World Health Organization (WHO) were established in all cases. Ovarian cancer histopathology was established in all cases by tissue biopsy of the tumor or post surgery from tumor cancer tissues. Patients with renal failure were excluded from our study due to very high HE4 concentration levels, undistinguishable from ovarian cancer. None of the patients had received chemo- or radiotherapy before blood sample collection.Table 1Characteristics of ovarian cancer patients and control groups: benign ovarian tumor and healthy subjectsStudy groupNumber of patientsEpithelial ovarian cancer patients100 (100%) • median age (range)59 (46--87)  - sub-type *serous epithelial*54 (54%) • median age (range)59 (46--81)  - sub-type *endometrioid epithelial*46 (46%) • median age (range)59 (49--87)Tumor stageIA-T~1a~N~0~M~0~5 (5%)IB-T~1b~N~0~M~0~7 (7%)IC-T~1c~N~0~M~0~13 (13%)IIA-T~2a~N~0~M~0~8 (8%)IIB-T~2b~N~0~M~0~9 (9%)IIC-T~2c~N~0~M~0~8 (8%)IIIA-T~3a~N~0~M~0~9 (9%)IIIB-T~3b~N~0~M~0~9 (9%)IIIC-T~3c~N~0~M~0~7 (7%)IV(metastases)25 (25%)Menopausal status:  **-** postmenopausal100 (100%)Benign ovarian tumor patients80 (100%) - type *cystis serous*40 (50%) - type *cystis endometriosis*40 (50%)Median age (range)54 (48--68)Menopausal status: - postmenopausal80 (100%)Healthy subjects80 (100%)Median age (range)55 (47--64)Menopausal status: - postmenopausal80 (100%)

Pretreatment staging procedures included physical and blood examinations, ultrasound scanning and chest X-rays. In addition, radioisotope bone scans, the examination of bone marrow aspirates, and brain and CT scans were performed where necessary.

The control groups were comprised of 80 benign ovarian tumor patients (*cystis serous* or *cystis endometrioides*) and 80 healthy volunteers. The benign ovarian tumor histopathology was established in all cases by tissue biopsy of the ovarian tumor or post surgery.

The healthy women group were also examined by a gynecologist prior to blood collection and subjects with a clinical history of endometriosis or mild gynecological conditions were excluded. Women included in the control group were volunteers without visible/perceptible changes in the adnexa and in the anamnesi. The group was examined by a gynecologist prior to blood collection and the ultrasound examination was performed in every case.

The ovarian cancer patients and the control group (benign lesions) were treated in the Department of Gynecology, University Hospital in Bialystok, Poland, in the years 2009--2014. The study was approved by the local Ethics Committee of the Medical University in Bialystok, numbers: R-I-002/314/2009 and R-I-002/262/2010 and all the patients gave their informed consent for study participation.

Biochemical analyses {#Sec4}
--------------------

Venous blood samples were collected from each patient. Blood was collected into a heparin sodium tube, centrifuged 1000 rpm for 15 min. to obtain plasma samples and stored at −85^0^ C until assayed. Tested metalloproteinase-7 (MMP-7) and tissue inhibitor of metalloroteinase-1 (TIMP-1) were measured with the enzyme-linked immunosorbent assay (ELISA) (Quantikine Human Total MMP-7 Immunoassay, Human TIMP-1 Immunoassay, R&D systems) according to the manufacturer's protocols. Duplicate samples were assessed for each patient.

The intra-assay coefficient of variation (CV%) of MMP-7 is reported to be 3.7% at a mean concentration of 4.58 ng/ml, SD = 0.168. The inter-assay coefficient of variation (CV%) of MMP-7 is reported to be 4.1% at a mean concentration of 4.82 ng/ml, SD = 0.198.The intra-assay coefficient of variation (CV%) of TIMP-1 -- 5.0% at a mean concentration of 6.95 ng/ml, SD = 0.35. The inter-assay coefficient of variation (CV%) of TIMP-1 -- 4.9% at a mean concentration of 6.90 ng/ml, SD = 0.34. The assay showed no significant cross-reactivity or interference with numerous human metalloproteinases and tissue inhibitors of metalloproteinases (TIMPs).

Plasma concentrations of CA125 and HE4 were measured by chemiluminescent microparticle immunoassay (CMIA) (Abbott, Chicago, IL, USA). The intra-assay CV for CA125 is reported to be 2.4% at a mean concentration of 43.5 U/ml, SD = 1.1. The inter-assay CV for CA125--3.9% at a mean concentration of 43.5 U/ml, SD = 1.7. The intra-assay CV for HE4--3.7% at a mean concentration of 39.0 pmol/L, SD = 1.4. The inter-assay CV for HE4--2.8% at a mean concentration of 39.0 pmol/L, SD = 1.1.

Statistical analysis {#Sec5}
--------------------

Statistical analysis was performed using the STATISTICA 8.0 PL program. A preliminary statistical analysis (Chi-square test) revealed that the distribution of MMP-7, TIMP-1 and tumor markers levels did not follow a normal distribution. Consequently, nonparametric methods were used to compare tumor marker levels between patient groups. Comparisons between two groups were performed using the Mann-Whitney test. In the case of multiple groups, Kruskal-Wallis tests were calculated with post hoc comparisons according to the Dwass-Steele-Critchlow-Fligner method. ROC analyses were utilised in the evaluation of the diagnostic power of tumor markers. Markers were compared by assessing the significance of differences between the areas under their corresponding ROC curves. In addition, markers were compared by assessing the differences in sensitivity and specificity obtained for the optimal cut-off points. The construction of the ROC curves was performed using the GraphRoc Program for Windows.

Data were presented as median and range. Statistically significant differences were defined as comparisons resulting in *p* \< 0.05. The Spearman rank correlation was used in the correlation analyses.

The *cut-off* of MMP-7 (5.04 ng/ml), TIMP-1 (253.33 ng/ml), HE4 (93.81 pmol/L) and CA125 (107.09 U/ml) were calculated as the 95th percentile from the control group of healthy blood donors.

Results {#Sec6}
=======

In the total group of ovarian cancer (OC) patients, plasma levels of MMP-7 (5.60 ng/ml), TIMP-1 (170.79 ng/ml) and tumor markers, HE4 (207.09 pmol/L) or CA125 (139.70 U/ml) were found to be statistically higher compared to the healthy subjects (3.25 ng/ml; 128.88 ng/ml; 54.00 pmol/L; 12.70 U/ml) (*p* \< 0.001, respectively) (Table [2](#Tab2){ref-type="table"}). Moreover, we observed significant differences between the concentrations of all the parameters when every stage of cancer advancement (I-IV) was compared with the corresponding control group (with the exception of TIMP-1 -- stage II): I -*p* \< 0.001 (MMP-7, HE4 and CA125); II - *p* \< 0.001 (in all cases); III - *p* \< 0.001 (MMP-7, HE4 and CA125) and *p* = 0.001 (TIMP-1); IV - *p* \< 0.001 (MMP-7, HE4 and CA125) and *p* = 0.011 (TIMP-1). Plasma concentrations of all aforementioned biomarkers were also significantly different in the advanced stages (III-IV) in comparison to those found in the early stages (I-II): MMP-7, TIMP-1, HE4 and CA125 in the comparison of stage III with stage I (*p* = 0.037; *p* = 0.005; *p* = 0.011; *p* = 0.002, respectively) and HE4 and CA125 in the comparison of stage III with stage II (*p* = 0.004; *p* = 0.013) or MMP-7, TIMP-1 and CA125 in the comparison of stage IV with I (*p* = 0.011; *p* = 0.033; *p* = 0.007), MMP-7 and CA125 in the comparison of stage IV with II (*p* = 0.010; *p* = 0.025) of tumor advancement.Table 2Plasma levels of MMP-7, TIMP-1, HE4 and CA 125 in tested groups (statistically significant when *p* \< 0.05)GroupsMMP-7\
(ng/ml)TIMP-1\
(ng/ml)HE4\
(pmol/L)CA125\
(U/ml)Ovarian cancer Median RangeStage I^a,\ b^4.76\
1.98--17.86^a^108.35\
4.60--328.90^a,\ b^118.70\
34.50--1093.80^a^66.73\
10.60--557.20Stage II^a,\ b^4.73\
2.24--18.00151.70\
15.20--839.00^a,\ b^120.90\
38.30--1205.70^a,\ b^61.45\
9.80--2060.78Stage III^a,\ b,\ d^7.92\
1.98--17.80^a,\ b,\ d^241.20\
26.00--554.70^a,\ b,\ d^650.55\
48.70--1810.60^a,\ b,\ d^766.20\
10.10--2742.00Stage IV^a,\ b,\ d^12.27\
2.00--27.40^a,\ b,\ d^252.60\
28.00--642.00^a,\ b^372.95\
37.80--1944.20^a,\ b,\ d^541.13\
14.30--8602.30Total group^a,\ b^5.60\
1.98--27.40^a,\ b^170.79\
4.60--839.00^a,\ b^207.09\
34.50--1944.20^a,\ b^139.70\
9.80--8602.30Control groups Median RangeBenign ovarian tumor total group3.18\
1.33--24.25107.00\
6.71--309.0657.70\
34.90--202.90^c^22.90\
5.80--748.00Healthy subjects3.25\
1.75--8.42128.88\
23.38--266.0954.00\
15.00--408.8912.70\
1.49--36.60^a^Statistically significant when comparing EOC patients with healthy subjects^b^Statistically significant when comparing EOC patients with benign ovarian tumor total group^c^Statistically significant when comparing patients with benign ovarian tumor and healthy subjects^d^Statistically significant when comparing EOC patients in stage III or IV with stage I or II

Ovarian cancer patients (total group) had statistically considerably higher levels of all the researched factors (*p* \< 0.001; in all cases) than patients with ovarian cysts (Table [2](#Tab2){ref-type="table"}). We also observed similar, significantly higher concentrations of MMP-7 in stages I-IV (*p* \< 0.001 in all cases), of TIMP-1 in stages III-IV (*p* \< 0.001), of HE4 in stages I-IV (*p* \< 0.001 in all cases) and of CA125 in stages II-IV (*p* = 0.002; *p* \< 0.001; *p* \< 0.001) of OC in comparison with the total benign lesions group.

We also noticed significant differences in the concentrations of CA125 when the ovarian cysts group was compared with the healthy subjects group (*p* \< 0.001).

Table [3](#Tab3){ref-type="table"} presents the diagnostic criteria of parameters tested in OC patients. We observed higher SE ranges of MMP-7 and tumor markers in more advanced ovarian tumor stages (exception -- TIMP-1). They were the highest for HE4. Interestingly, MMP-7 presented better results than CA125 in the groups with stage I-II (Table [3](#Tab3){ref-type="table"}). Combined use of the studied biomarkers resulted in an increase in diagnostic SE to a very high range in stage I: 75% and II: 81%for the combination of MMP-7 with HE4 and CA125. The maximum ranges (96--100%) were obtained for the combinations of MMP-7 + HE4; HE4 + CA125; MMP-7 + CA125 as well as for the combination of MMP-7 or its tissue inhibitor with both markers in stages III-IV (Table [4](#Tab4){ref-type="table"}).Table 3The diagnostic criteria of MMP-7, TIMP-1, HE4 and CA 125 in epithelial ovarian cancer patientsEpithelial ovarian cancerDiagnostic criteria (%)MMP-7TIMP-1HE4CA125Stage ISE4245435SP95959598PPV78258190NPV83738075Stage IISE46235438SP95959598PPV78678290NPV81767182Stage IIISE77357577SP95959598PPV87758895NPV92788690Stage IVSE79168883SP95959598PPV86808695NPV93769092Total groupSE61206858SP95959598PPV93879698NPV61446660 Table 4The diagnostic criteria of MMP-7, TIMP-1 in combination with HE4 and CA 125 in epithelial ovarian cancer patientsEpithelial ovarian cancerDiagnostic criteria (%)MMP-7 + HE4MMP-7 + CA125TIMP-1 + HE4TIMP-1 + CA 125HE4 + CA 125MMP-7 + HE4 + CA125TIMP-1 + HE4 + CA 125Stage ISE71635442637563SP91949194948989PPV74796871797268NPV89878481879186Stage IISE62656242738173SP91949194948989PPV73817373837573NPV85878580909289Stage IIISE9692888596100100SP91949194948989PPV81867985867979NPV9897959498100100Stage IVSE92967983969696SP91949194948989PPV79857683857777NPV97989294989898Total groupSE80817163828883SP91949194948989PPV93959294959392NPV75746762778377

The diagnostic specificities of the biomarkers tested (SP) presented high, comparable values: 95%--98% (Table [3](#Tab3){ref-type="table"}).

PPV in the total group of OC patients had very high values (87%--98%) for all the parameters tested, NPV was the highest for HE4 (66%) (Table [3](#Tab3){ref-type="table"}). Combined use of the biomarkers studied for the remaining group resulted in an increase in NPV (83%) values and a decrease in PPV (95%) (Table [4](#Tab4){ref-type="table"}). A maximum range of NPV (98--100%) was obtained for the combination of MMP-7 with HE4 and/or CA125 in stages III-IV of ovarian cancer.

To evaluate the dependence between the investigated parameters we used the Spearman's rank correlation (Table [5](#Tab5){ref-type="table"}). There were only positive significant correlations in the ovarian cancer total group: between the HE4 and CA125 concentrations (*R* = 0.39; *p* \< 0.001), between the CA125 and MMP-7 concentrations (*R* = 0.27; *p* = 0.007,) between the CA125 and TIMP-1 concentrations (*R* = 0.30; *p* = 0.002), between the HE4 and MMP-7 concentrations (*R* = 0.35; *p* \< 0.001), and between the HE4 and TIMP-1 or the MMP-7 and TIMP-1 concentrations (*R* = 0.24; *p* = 0.014). Furthermore, significant positive correlations were noticed between the HE4 and MMP-7 (*R* = 0.24; *p* = 0.008) or TIMP-1 (*R* = 0.27; *p* = 0.002) concentrations as well as between the MMP-7 and TIMP-1 concentrations (*R* = 0.25; *p* = 0.006) in the ovarian cysts group.Table 5The Spearman rank correlation for MMP-7, TIMP-1, HE4 and CA125 in tested groupsMMP-7TIMP-1HE4CA125EOCMMP-7R1.000.240.350.27p**0.014\<0.0010.007**TIMP-1R0.241.000.240.30p**0.0140.0140.002**HE4R0.350.241.000.39p**\<0.0010.014\<0.001**CA125R0.270.300.391.00p**0.0070.002\<0.001**Benign Ovarian TumorMMP-7R1.000.250.240.06p**0.0060.008**0.526TIMP-1R0.251.000.270.001p**0.0060.002**0.966HE4R0.240.271.000.17p**0.0080.002**0.070CA125R0.060.0010.171.00p0.5260.9660.070Healthy SubjectsMMP-7R1.000.12−0.12−0.05p0.3360.3310.682TIMP-1R0.121.000.13−0.03p0.3360.2860.794HE4R−0.120.131.000.14p0.3310.2860.268CA125R−0.05−0.030.141.00p0.6820.7940.268Bold data are statistically significant when *p* \< 0.05

The relationship between diagnostic SE and SP was illustrated by the ROC (receiver-operating characteristics) curve. The AUCs of all compared biomarkers (with the exception of TIMP-1) were significantly higher compared to AUC = 0.5 in every studied OC group (Tables [6](#Tab6){ref-type="table"}, [7](#Tab7){ref-type="table"}). We demonstrated that the CA125 (0.8988) and HE4 (0.8836) areas under the ROC curve were the largest in the total group of OC (Table [6](#Tab6){ref-type="table"}; Fig. [1](#Fig1){ref-type="fig"}). The AUCs of CA125 and HE4 were also the largest in the groups of patients with stages I-IV of the disease. Combining the studied parameters resulted in a further increase in the area under the ROC curve in every case (especially for the combination of MMP-7 + HE4 + CA125) to the value: 0.8635 in stage I; 0.9385 in stage II; 0.9935 in stage III, 0.9788 in stage IV and 0.9382 in the total OC group (Table [7](#Tab7){ref-type="table"}). It should be emphasised that the areas under the ROC curve in various stages of cancer for MMP-7 in combination with HE4 or CA125 were as large as those for the combination of CA125 and HE4.Table 6The diagnostic criteria of the ROC curve for MMP-7, TIMP-1, HE4 and CA125 in epithelial ovarian cancer patientsEpithelial ovarian cancerThe ROC criteriaMMP-7TIMP-1HE4CA 125Stage IAUC0.7801^a^0.57690.8343^a^0.8324^a^SE0.06930.07180.05820.047195% C.I.0.644--0.9160.436--0.7180.720--0.9480.740--0.925*p*AUC = 0.5**0.0001**0.2840**\<0.001\<0.001**Stage IIAUC0.7938^a^0.61090.8462^a^0.8825^a^SE0.06390.07720.04790.039795% C.I.0.669--0.9190.460--0.7620.752--0.9400.805--0.960*p*AUC = 0.5**\<0.001**0.1506**\<0.001\<0.001**Stage IIIAUC0.8905^a^0.7740^a^0.9521^a^0.9331^a^SE0.04850.06430.02880.032795% C.I.0.796--0.9860.648--0.9000.896--1.0080.869--0.997*p*AUC = 0.5**\<0.001\<0.001\<0.001\<0.001**Stage IVAUC0.8679^a^0.7314^a^0.8994^a^0.9458^a^SE0.06240.07780.05110.025295% C.I.0.746--0.9900.579--0.8840.799--1.0000.896--0.995*p*AUC = 0.5**\<0.0010.0029\<0.001\<0.001**Total groupAUC0.8335^a^0.6372^a^0.8836^a^0.8988^a^SE0.3300.04250.02630.023595% C.I.0.769--0.8980.554--0.7210.832--0.9350.853--0.945*p*AUC = 0.5**\<0.0010.0013\<0.001\<0.001***C.I.* -- confidence intervals of AUC^a^Statistically significant when comparing tested parameters AUC's with 0.5 AUCBold data are statistically significant when *p* \< 0.05 Table 7The diagnostic criteria of the ROC curve for MMP-7, TIMP-1in combination with HE4 and CA125 in epithelial ovarian cancer patientsEOCThe ROC criteriaMMP-7 + HE4MMP-7 + CA 125TIMP-1 + HE4TIMP-1 + CA 125HE4 + CA 125MMP-7 + HE4 + CA 125TIMP-1 + HE4 + CA 125Stage IAUC0.8596^a^0.7981^a^0.7795^a^0.6532^a^0.8474^a^0.8635^a^0.8071^a^SE0.05710.06890.06680.07300.05730.05660.064695% C.I.0.748--0.9720.663--0.9330.648--0.9100.510--0.7960.735--0.9600.752--0.9740.681--0.934*p*AUC = 0.5**\<0.001\<0.001\<0.0010.0359\<0.001\<0.001\<0.001**Stage IIAUC0.8456^a^0.9284^a^0.8290^a^0.7479^a^0.9331^a^0.9385^a^0.8982^a^SE0.05210.02620.05560.07220.02550.02340.040195% C.I.0.744--0.9480.877--0.9800.720--0.9380.607--0.8890.883--0.9830.893--0.9840.820--0.977*p*AUC = 0.5**\<0.001\<0.001\<0.0010.006\<0.001\<0.001\<0.001**Stage IIIAUC0.9864^a^0.9704^a^0.9657^a^0.9349^a^0.9893^a^0.9935^a^0.9923^a^SE0.00850.02330.02250.04120.00700.00520.006095% C.I.0.970--1.0030.925--1.0160.922--1.0100.854--1.0160.976--1.0030.983--1.0040.981--1.004*p*AUC = 0.5**\<0.001\<0.001\<0.001\<0.001\<0.001\<0.001\<0.001**Stage IVAUC0.9513^a^0.9519^a^0.9673^a^0.9423^a^0.9487^a^0.9788^a^0.9526^a^SE0.04060.03990.01550.03290.03700.01190.040595% C.I.0.872--1.0310.874--1.0300.937--0.9980.878--1.0070.876--1.0210.955--1.0020.873--1.032*p*AUC = 0.5**\<0.001\<0.001\<0.001\<0.001\<0.001\<0.001\<0.001**Total groupAUC0.9109^a^0.9137^a^0.8858^a^0.8205^a^0.9309^a^0.9382^a^0.9202^a^SE0.02370.02390.02630.03320.02050.01980.022295% C.I.0.864--0.9570.867--0.9610.834--0.9370.755--0.8850.891--0.9710.899--0.9770.877--0.964*p*AUC = 0.5**\<0.001\<0.001\<0.001\<0.001\<0.001\<0.001\<0.001***C.I.* -- confidence intervals of AUC^a^Statistically significant when comparing tested parameters AUC's with 0.5 AUCBold data are statistically significant when *p* \< 0.05 Fig. 1Diagnostic criteria of ROC curve for tested parameters in total EOC group

Discussion {#Sec7}
==========

Enhanced activity of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) has been proven to be closely associated with tumor aggressiveness, metastasis and poor prognosis \[[@CR15], [@CR26]\]. In this study we investigated the diagnostic usefulness of MMP-7 and TIMP-1 separately, and in combination with HE4 and CA125, which may improve the effectiveness of non-invasive diagnostics in patients with epithelial ovarian malignancies. Furthermore, we performed a comparison of the received results with the control group results (benign ovarian lesions patients and healthy subjects). Additionally, we estimated the diagnostic utility of the aforementioned parameters in correlation to the stage of cancer disease.

Our results showed significantly higher plasma concentrations of the commonly used tumor markers in every stage of advancement as well as in the total OC group in comparison to the healthy subjects group and these results are in line with our previous papers \[[@CR13], [@CR28]\] and with research results published by other authors \[[@CR29], [@CR30]\]. We found comparable results regarding MMP-7 in the ovarian cancer \[[@CR31]\]. Moreover, the overexpression of this metalloproteinase was associated with poor survival and/or correlated with the tumor stage of various malignancies \[[@CR32]--[@CR35]\]. Our results are consistent with the results of Määttä et al. \[[@CR36]\] who observed increased levels of TIMP-1 in the course of ovarian cancer, although the tested group was considerably smaller (22 cases) and composed of *serous*, *mucinous* and others malignant ovarian tumors. These data are also very similar to the studies of researchers who compared patients with breast cancer \[[@CR37]\] with healthy volunteers.

In opposition to our findings, Acar et al. \[[@CR31]\] found no significant differences in serum MMP-7 levels in patients with benign ovarian disease (only 10 cases were included) when compared to patients with malignant disease. The results reported in the available literature regarding TIMP-1 \[[@CR36]--[@CR38]\] correspond to the results of the current study and to our previous publications regarding breast cancer \[[@CR39], [@CR40]\]. Regardless of the menopausal status and composition of the groups compared, statistically higher concentrations of comparative tumor markers (*p* = 0.001 up to *p* \< 0.0001) were observed in ovarian cancer groups in comparison with benign diseases control groups \[[@CR12], [@CR29], [@CR30], [@CR41]\]. These results correspond to our previous publications \[[@CR13], [@CR28]\]. Other researchers, in line with the present study, have reported a lack of statistically significant differences in serum MMP-7 concentrations between benign ovarian lesions and healthy women groups \[[@CR31]\]. By contrast, Beeghly-Faidel et al. \[[@CR42]\] found a significantly higher MMP-7 expression in endometrial hyperplasia in comparison with normal endometrium. We were unable to confirm our findings regarding TIMP-1 in the published literature since no reports on the subject are available. Our present observations confirm the results of our previous study, which found significantly higher concentrations of CA125 in a group of 70 postmenopausal women with benign lesions of the ovary (cysts) \[[@CR43]\].

The Spearman's rank correlation test revealed that the degree of correlation between the concentrations of MMP-7, TIMP-1, HE4 and CA125 was not particularly strong (R:0.24--0.39).

This may indicate that each of the markers was elevated independently of the remaining ones and supports the proposition of a combined analysis. Unfortunately, we could not compare our data regarding MMP-7 and tissue inhibitor of metalloproteinase −1 with other publications. A positive correlation between TIMP-1 and CA15--3 concentrations in a group including 100 breast cancer patients (stages I-IV) (*R* = 0.28) has also been previously revealed \[[@CR39]\]. Some authors have demonstrated significant positive correlations between CA125 and HE4 levels in patients with ovarian malignancies (*R* = 0.54) \[[@CR44], [@CR45]\].

The present study demonstrated that diagnostic sensitivity was the highest for HE4, although SE of MMP-7 reached equal or even higher values than CA125, especially in stages I-II. Our results are in agreement with the published literature \[[@CR29], [@CR46]\]. It is worth emphasizing that we found a maximum increase in diagnostic sensitivity for the combination of MMP-7 with both tumor markers to 75% in stage I, even to 81%--100% in stages II-IV as compared with the use of either marker alone or of both comparative tumor markers together. Several studies have confirmed this observation - they found sensitivity to be greater than in either marker used alone: MMP-7, CCL18 (CC chemokine 18), CCL11 (CC chemokine 11) and CA125 in ovarian cancer (SE in the early stages 94.4%) \[[@CR46]\]. This conclusion is also in accordance with our previous papers in which the diagnostic criteria of selected cytokines and aforementioned tumor markers were evaluated in various gynecological malignancies \[[@CR47], [@CR48]\]. Diagnostic specificity (SP) reached very high and equal values for all biomarkers studied and this was in accordance \[[@CR40], [@CR43]\] with the available literature in the course of various malignant and benign diseases.

Notably, MMP-7 revealed high and comparable values of PPV and NPV to the values presented by HE4 and CA125 in every stage of advancement and in the total OC group. In the current study, the combination of both comparative tumor markers with MMP-7 had unquestionably higher NPV value \~100%. Unfortunately, we were unable to compare the findings concerning our diagnostic panel with the papers published since no reports on the subject are available. Interestingly, the presented results of the classic tumor markers diagnostic criteria in OC are partially in accordance with a publication by Hamed et al. \[[@CR29]\] who observed higher values of PPV and NPV for HE4 or CA125 separately (93.1%/80.7% and 92.7%/87.2%, respectively) in 30 patients with epithelial ovarian cancer versus 20 healthy women of varying menopausal status.

The area under the ROC curve (AUC) of 1 indicates a desirable, high diagnostic power of a test. Following our analysis, HE4 (0.8836) and CA125 (0.8988) showed the largest areas under the ROC curve in the total group of ovarian cancer as well as in the groups divided according to tumor stage. Moreover, we demonstrated that the utilisation of a combined panel of MMP-7 with both known tumor markers undoubtedly improved cancer detection in every stage, but especially in the early stages of the disease (0.8343 and 0.8324 vs 0.8635; respectively -- I stage). In line with the present data, preoperative serum TIMP-1 concentration showed insufficient diagnostic power (AUC = 0.730) in differentiating between low malignant potential and malignant ovarian tumors \[[@CR36]\]. In a few previous publications the AUC values for differentiating ovarian cancer were significantly higher for the combination of various biomarkers \[[@CR36], [@CR49]\], which is in line with our findings \[[@CR13], [@CR28], [@CR43]\]. Differences in study results might be due to differences in the histological types or disease stages of ovarian cancer and in the number of patients enrolled in each study.

Conclusions {#Sec8}
===========

In summary, to the authors' knowledge, our report is the first to evaluate the diagnostic usefulness of MMP-7 and TIMP-1 independently and, especially, in combination with both established ovarian tumor markers. The results of this study suggest that combining MMP-7, HE4 and CA125 measurements might enable the improved, early detection of selected histological types of EOC when compared with the use of either marker alone. Moreover, the investigated metalloproteinase presented similar to HE4 and CA125 diagnostic usefulness in opposition to TIMP-1 whose presented diagnostic usefulness was undoubtedly insufficient.
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:   α-fetoprotein

AUC

:   Area under ROC curve

CA 125

:   Carbohydrate antigen 125

CA19--9

:   Carbohydrate antigen 19--9

CCL

:   CC chemokine

CEA

:   Carcinoembryonic antigen

CMIA

:   Chemiluminescent microparticle immunoassay

CRP

:   C Reactive Protein

CT

:   Computed tomography

CV

:   Coefficient of variation

ELISA

:   Enzyme-linked immunosorbent assay

EOC

:   Epithelial ovarian cancer

FIGO

:   International Federation of Gynecology and Obstetrics

HE4

:   Human epididymis protein 4

HGFs

:   Hematopoietic growth factors

M-CSF

:   Macrophage-colony stimulating factor

MMP-7

:   Metalloproteinase 7

NPV

:   Negative predictive value

OC

:   Ovarian cancer

PPV

:   Positive predictive value

ROC

:   Receiver-operating characteristics

SAA

:   Serum amyloid A

SD

:   Standard deviation

SE

:   Diagnostic sensitivity

SP

:   Diagnostic specificity

TIMP-1

:   Tissue inhibitor of metalloproteinase-1

TNM

:   Tumor-nodulus-metastasis classification

VEGF

:   Vascular endothelial growth factor

WHO

:   World Health Organization

βFGF

:   Basic fibroblast growth factor
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